Researchers find new treatment to reverse COPD, other lung diseases

In a study conducted on mice, researchers found a receptor that could reverse inflammatory responses and combat chronic obstructive pulmonary disease (COPD) and other lung diseases.

The findings, published in The FASEB Journal, found that the helpful receptor is one characterized for advanced glycan end-products (RAGE)-specific antagonist chemical compound, FPS-ZM1.

"RAGE disturbances in pulmonary disorders are precise and effective strategies with beneficial clinical effects," said Se-Ran Yang, PhD, an author on the study and an associate professor at the Department of Thoracic and Cardiovascular Surgery in the School of Medicine at Kangwon National University in Gangwon, Korea. "Blockade of RAGE as a novel clinical therapeutic for COPD ameliorates emphysema/COPD development and progression."

The researchers investigated the efficacy of the receptor in both vivo and in vitro COPD models to see what the molecular mechanism by which RAGE influences COPD.

They found that RAGE was association with the up-regulation of DAMP-related signaling pathways. FPS-ZM1 also reversed emphysematous lung symptoms in the mice by a significant margin.

"No one expected the pathogenic roots of COPD to be simple, and this study gives us an indication of the complexity involved.," said Thoru Pederson, PhD, editor-in-chief of The FASEB Journal. "The current pharmacological armamentarium is limited, and studies like this are thus extremely valuable as a foundation."

 

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.